News

Jun 05, 2025

Zhimeng’s Innovative HBV Core Protein-Targeted Drug Reached Agreement with CDE for Initiating the Phase 3 Clinical Trial

Oct 19, 2023

Zhimeng Biopharma CB03 Received Orphan Drug Designation from the US FDA - A Potassium Ion Channel Opener for Amyotrophic Lateral Sclerosis

Feb 01, 2023

Zhimeng Biopharma Entered into A Global Exclusive Licensing Agreement with GlaxoSmithKline in HBV

Dec 27, 2022

Zhimeng Biopharma Announces Dosing of First Subject in Phase II Clinical Trial of Its Novel HBV Capsid Assembly Modulator

May 12, 2022

Zhimeng Biopharma Announces Dosing of First Subject of Its Novel Antiepileptic Drug Candidate CB03 in First-in-Human Phase I Clinical Trial

Apr 02, 2022

Zhimeng Biopharma Announces Dosing of First Subject in First-in-Human Phase I Clinical Trial of CB06

Dec 17, 2021

Zhimeng Biopharma Announces FDA Approval of its Investigational New Drug (IND) Application for CB06-036

Nov 12, 2021

News Release from Shanghai Zhimeng Biopharma, Inc

Nov 08, 2021

Zhimeng Biopharma announces the closing of $55 million series B financing

Oct 09, 2021

Shanghai Zhimeng Biopharma, Inc. announces the completion of phase 1a clinical study on its novel HBV capsid inhibitor ZM-H1505R and the presentation of the results in the upcoming 2021 annual meeting of the America Association for the Study of Liver Diseases (AASLD) held in November 12-15, 2021

prev
1
2
next

Get in touch

Contact Us About Us Leadership Team Scientific Advisors